[
    "U (1.2 eq). 30% aqueous solution OfNH<sub>4</sub>OH (3 eq) was then slowly added and the reaction mixture was then stirred at O<sup>0</sup>C for 2 h. The mixture was poured into a saturated aqueous solution of sodium hydrogen bicarbonate and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine and water, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude compound was purified by automated SiO<sub>2</sub> flash chromatography system using solvent gradient of 40% EtO Ac/Hex to 100% EtO Ac/Hex. M+1 (+ESI) = 605.641 \n\n EXAMPLE I l</p>Synthesis of (S)-N-[(S)-Cyano-(4-cyano-2-fluoro-benzyl)-methyl]-2-{(S)-l-[4'-((R)-2,2-difluoro- l-hydroxy-ethyl)-biphenyl-4-yl]-2,2,2-trifluoro-ethylamino}-3-methyl-butyraniide</p></p>(S)-N-[(S)-Cyano-(4-cyano-2-fluoro-benzyl)-methyl]-2-{(S)-l-[4'-((R)-2,2- difluoro-l-hydroxy-ethyl)-biphenyl-4-yl]-2,2,2-trifluoro-ethylamino}-3-methyl-butyramide was prepared from N<sup>2</sup>-[(15)-l-(4-bromophenyl)-2,2,2-trifluoroethyl]-iV-[(15)-l-cyano-2-(4-cyano-2- fluorophenyl)ethyl]-L-valinamide and (li?)-2,2-difluoro-l-[4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl]ethanol (described in U.S. Patent No. 7,407,959, hereby incorporated by reference in its entirety.) using procedure described in step 2 of Example 10.</p>M+l (+ESI) = 603.2</p>Using the methods described above, the following compounds were prepared: \n\n</p>Table 1</p>Compound Assay</p>Ex. Compound Name Characterization data IC50 (nivn</p>(S)-4,4-Dichloro-\u039b/-[(S)-cyano-(4- cyano-2-fluoro-benzyl)-methyl]-2-[(S)-</p>M+1 , +ESI= 655 and 657 0.14 2,2,2-trifluoro-1-(4'-methanesulfonyl- biphenyl-4-yl)-ethyiamino]-butyramide \n\n</p>(S)-4-Fluoro-4-methyl-2-[(S)-2,2,2- trifluoro-1-(4'-methanesulfonyl- biphenyl-4-yl)-ethylamino]-pentanoic M+1 , +ESI= 633.2 0.95 acid [(S)-I -cyano-2-(4-cyano-2-fluoro- phenyl)-ethyl]-amide \n\n \n\n</p></p></p></p></p></p></p></p></p>Compound Assay</p>Ex. Compound Name Characterization data IC50 (nM)</p>(S)-2-{(S)-1 -[4'-( 1 -Cyano-cyclopropyl)- biphenyl-4-yl]-2,2,2-trifluoro-</p>27 ethylamino}-4-fluoro-4-methyl- M+1 , +ESI= 577.2 10.4 pentanoic acid ((S)-I -cyano-2-phenyl- ethyl)-amide \n\n</p>(S)-4-F1uoro-4-methyl-2-((S)-2,2,2- trifluoro-1 -{4'-[1 -(morpholine-4-</p>28 carbonyl)-cyclopropyl]-biphenyl-4-yl}- M+1 , +ESI= 665.2 3.1 ethylamino)-pentanoic acid ((S)-I- cyano-2-phenyl-ethyl)-amide \n\n</p>(S)-4-Fluoro-4-methyl-2-{(S)-2,2,2- trifluoro-1-[4'-(1-[1 ,2,4]oxadiazol-3-yl-</p>29 cyclopropyl)-biphenyl-4-yl]- M+1 , +ESI= 620.2 20 ethylamino}-pentanoic acid ((S)-I- cyano-2-phenyl-ethyl)-amide \n\n \n\n</p></p></p></p></p></p></p>Compound Assay</p>Ex. Compound Name Characterization data IC50 (nivn</p>1 -[4'-((S)-I -{(S)-1 -[((S)-Benzyl-cyano- metnyl)-carbamoyl]-2-methyl-</p>48 propylamino}-2,2,2-trifluoro-ethyl)- M+1 , +ESI= 563.2 0.7 biphenyl-4-yl]-cyclopropsinecarboxylic acid amide \n\n</p>(S)-\u039b/-((S)-Benzyl-cyano-methyl)-3-</p>49 methyl-2-[(S)-2,2,2-trifluoro-1-(4- M+1 , +ESI= 481.2 5.6 pyridin-4-yl-phenyl)-ethylamino]- butyramide \n\n</p>(S)-\u039b/-((S)-Benzyl-cyano-methyl)-2-</p>50 {(S)-1-[4'-((R)-2,2-difluoro-1-hydroxy- M+1 , +ESI= 560.2 3.2 ethyl)-biphenyl-4-yl]-2,2,2-trifluoro- ethylamino}-3-methyl-butyramide \n\n \n\n</p></p>Compound Assay</p>Ex. Compound Name Characterization data IC50 (nM)</p>1 -[4'-((S)-I -{(S)-1 -[((S)-Benzyl-cyano- methyl)-carbamoyl]-3-fluoro-3-methyl-</p>54 butylamino}-2,2,2-trifluoro-ethyl)- M+1 , +ESI= 677.2 9.4 biphenyl-4-yl]-cyclopropanecarboxylic acid (2,2,2-trifluoro-ethyl)-amide \n\n</p>1 -[4'-((S)-I -{(S)-1 -[((S)-Benzyl-cyano- methyl)-carbamoyl]-3-fluoro-3-methyl-</p>55 butylamino}-2,2,2-trifluoro-ethyl)- M+1 , +ESI= 652.3 1.9 biphenyl-4-yl]-cyclopropanecarboxylic acid carbamoylmethyl-amide \n\n</p>1 -[4'-((S)-I -{(S)-1 -[((S)-Benzyl-cyano- methyl)-carbamoyl]-3-fluoro-3-methyl-</p>56 butylamino}-2,2,2-trifluoro-ethyl)- M+1 , +ESI= 635.3 3.7 biphenyl-4-yl]-cyclopropanecarboxylic acid cyclopropylamide \n\n \n\n</p></p>Compound Assay</p>Ex. Compound Name Characterization data IC50 (nivn</p>(S)-4-Fluoro-4-methyl-2-[(S)-2,2,2- trifluoro-1-(4'-methanesulfonyl-</p>60 biphenyl-4-yl)-ethylamino]-pentanoic M+1 ,+ESI= 591.2 6.4 acid ((S)-cyano-pyridin-4-ylmethyl- methyl)-amide</p>(S)-\u039b/-[(S)-Cyano-(2-fluoro-4- trifluoromethyl-benzyl)-methyl]-2-{(S)-</p>61 1 -[4'-((R)-2,2-difluoro-1 -hydroxy- M+1 , +ESI= 646.2 1.5 ethyl)-biphenyl-4-yl]-2,2,2-trifluoro- ethylamino}-3-methyl-butyramide \n\n</p>(S)-\u039b/-[(S)-Cyano-(2-fluoro-4- trifluoromethyl-benzyl)-methyl]-3-</p>62 methyl-2-[(S)-2,2,2-trifluoro-1-(4'- M+1 , +ESI= 644.2 0.4 methanesulfonyl-biphenyl-4-yl)- ethylamino]-butyramide \n\n \n\n</p></p></p>Compound Assay</p>Ex. Compound Name Characterization data IC50 (nivn</p>(S)-\u039b/-[(S)-Cyano-(4-cyano-2-fluoro- benzyl)-methyl]-2-cyclopropyl-2-{(S)-</p>69 1 -[4'-((R)-2,2-difluoro-1 -hydroxy- M+1 , +ESI= 601.2 4.3 ethyl)-biphenyl-4-yl]-2,2,2-trifluoro- ethylamino}-acetamide \n\n</p>(S)-\u039b/-[(S)-(4-Bromo-2,6-difluoro- benzyl)-cyano-methyl]-3-methyl-2-</p>70 [(S)-2,2,2-trifluoro-1-(4'- M+1 , +ESI= 672.1 and 674.1 0.6 methanesulfonyl-biphenyl-4-yl)- ethylaminoj-butyramide \n\n</p>(S)-\u039b/-[(S)-(4-Bromo-2,6-difluoro- benzyl)-cyano-methyl]-2-{(S)-1-[4'-</p>71 ((R)-2,2-difluoro-1-hydroxy-ethyl)- M+1 , +ESI= 672.1 and 674.1 2.1 biphenyl-4-yl]-2,2,2-trifluoro- ethylamino}-3-methyl-butyramide \n\n \n\n</p>Compound Assay</p>Ex. Compound Name Characterization data IC50 (nM)</p>(S)-\u039b/-f(S)-Cyano-(4-cyano-2,6- difluoro-benzyl)-metnyl]-3-methyl-2-</p>72 [(S)-2,2,2-trifluoro-1-(4'- M+1 ,+ESI= 619.2 0.5 methanesulfonyl-biphenyl-4-yl)- ethylamino]-butyramide \n\n</p>(S)-\u039b/-[(S)-Cyano-(4-cyano-2,6- difluoro-benzyl)-methyl]-2-{(S)-1-[4'-</p>73 ((R)-2,2-difluoro-1-hydroxy-ethyl)- M+1 , +ESI= 621.2 0.7 biphenyl-4-yl]-2,2,2-trifluoro- ethylamino}-3-methyl-butyramide \n\n</p>(S)-4-Fluoro-4-methyl-2-[(S)-2,2,2- trifluoro-1-(4'-methanesulfonyl-</p>74 biphenyl-4-yl)-ethylamino]-pentanoic M+1 , +ESI= 607.2 39 acid [(S)-cyano-(1 -oxy-pyridin-3- yimethyl)-methyl]-amide \n\n \n\n</p></p>10 \n\n</p>Pharmaceutical Composition</p>As a specific embodiment of this invention, 100 mg of (2S)-4,4-dichloro-N-[(lS)- l-cyano-2-(4-cyano-2-fluorophenyl)ethyl]-2-({(lS)-2,2,2-trifluoro-l-[4'- (methylsulfonyl)biphenyl-4-yl] ethyl }amino)butanamide, is formulated with sufficient finely divided lactose to provide a total amount of 580 to 590 mg to fill a size 0, hard-gelatin capsule.</p>The compounds disclosed in the present application exhibited activity in the following assays. In addition, the compounds disclosed in the present application have an enhanced pharmacological profile relative to previously disclosed compounds.</p>Cruzipain Assay</p>Serial dilutions (1/3) from 500 \u03bcM down to 0.0025 \u03bcM of test compounds were prepared in dimethyl sulfoxide (DMSO). Then an aliquot of compound in DMSO from each dilution were added in to a black 384 well polystyrene plate (Corning Cat#357"
]